MedMira Inc
XTSX:MIR

Watchlist Manager
MedMira Inc Logo
MedMira Inc
XTSX:MIR
Watchlist
Price: 0.095 CAD 11.76% Market Closed
Market Cap: 72m CAD
Have any thoughts about
MedMira Inc?
Write Note

MedMira Inc
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

MedMira Inc
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
MedMira Inc
XTSX:MIR
Net Change in Cash
CA$2.1m
CAGR 3-Years
N/A
CAGR 5-Years
88%
CAGR 10-Years
32%
Titan Medical Inc
TSX:TMD
Net Change in Cash
-$6.7m
CAGR 3-Years
N/A
CAGR 5-Years
11%
CAGR 10-Years
N/A
Profound Medical Corp
TSX:PRN
Net Change in Cash
-$6.5m
CAGR 3-Years
15%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Opsens Inc
TSX:OPS
Net Change in Cash
-CA$5.7m
CAGR 3-Years
-13%
CAGR 5-Years
-28%
CAGR 10-Years
N/A
Theralase Technologies Inc
XTSX:TLT
Net Change in Cash
CA$21.1k
CAGR 3-Years
N/A
CAGR 5-Years
-54%
CAGR 10-Years
-39%
O
Ondine Biomedical Inc
LSE:OBI
Net Change in Cash
-CA$10.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

MedMira Inc
Glance View

Market Cap
66.7m CAD
Industry
Health Care

MedMira, Inc. is a biotechnology company, which through its subsidiaries, engages in the research, development, manufacture, and commercialization of diagnostics and technology platforms. The company is headquartered in Halifax, Nova Scotia. The firm is engaged in the development and commercialization of rapid diagnostics and technology platforms. The MedMira Rapid Vertical Flow (RVF) Technology platform is the basis for the Company's line of rapid tests. Its technology platform detects multiple biomarkers specific to several diseases using a single cartridge. Its Multiplo line of rapid tests for human immunodeficiency virus (HIV), Hepatitis B and C, and syphilis uses the platforms capabilities to deliver approximately up to four test results using one test cartridge and one drop of specimen. The company also has a research product line that facilitates technology licensing, contract manufacturing, and regulatory consulting. The firm sells its rapid tests through a network of medical distributors and strategic business development partners to customers in all sectors of the healthcare industry, including laboratories, hospitals and point-of-care clinics, among others.

MIR Intrinsic Value
0.002 CAD
Overvaluation 98%
Intrinsic Value
Price

See Also

What is MedMira Inc's Net Change in Cash?
Net Change in Cash
2.1m CAD

Based on the financial report for Jul 31, 2024, MedMira Inc's Net Change in Cash amounts to 2.1m CAD.

What is MedMira Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 10Y
32%

Back to Top